PeptidePedia
Limited Human Evidence

SS-31

A mitochondria-targeting tetrapeptide (elamipretide) that binds cardiolipin on the inner mitochondrial membrane; it has been tested in multiple human trials and gained FDA accelerated approval for the ultra-rare Barth syndrome in 2025, though several other primary endpoints were not met.

In plain English

SS-31, better known by its drug name elamipretide, is a small four-amino-acid peptide designed to home in on mitochondria, the energy factories inside cells. It sticks to a membrane fat called cardiolipin and is thought to help damaged mitochondria make energy more efficiently. Unlike most peptides sold for 'research,' SS-31 has been through real, large human clinical trials in serious diseases, including a rare genetic heart-and-muscle condition (Barth syndrome), broader mitochondrial muscle disease, dry age-related macular degeneration, and heart failure. The honest picture is mixed: many of these trials did NOT meet their main goals, but the Barth syndrome program produced enough signal that the FDA granted accelerated (conditional) approval in 2025. It is not an approved or proven therapy for general energy, anti-aging, or wellness use.

What it is

SS-31 is a synthetic, cell-permeable tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. It is the same molecule developed pharmaceutically as elamipretide, and previously studied under the codes MTP-131 and the trial name Bendavia by Stealth BioTherapeutics. It is delivered by subcutaneous injection in clinical studies.

Mechanism (summary)

SS-31 carries a net positive charge that lets it concentrate inside mitochondria and bind selectively to cardiolipin, a phospholipid unique to the inner mitochondrial membrane. By associating with cardiolipin, it is proposed to stabilize the folded cristae architecture of the inner membrane, help keep electron-transport-chain components (such as cytochrome c) properly organized, reduce excess reactive oxygen species, and support more efficient ATP production. Because cardiolipin damage is a common feature of stressed or diseased mitochondria, the peptide is being studied wherever mitochondrial dysfunction is central.

Why people research it

  • Barth syndrome, an ultra-rare X-linked disorder of cardiolipin metabolism causing cardiomyopathy and muscle weakness
  • Primary mitochondrial myopathy, where genetic defects impair muscle energy production
  • Dry age-related macular degeneration and geographic atrophy, where photoreceptor mitochondrial decline is implicated
  • Heart failure and ischemia-reperfusion injury, where preserving mitochondrial function may protect cardiac tissue
  • Broader interest in mitochondrial decline as a driver of aging and fatigue

Human evidence

SS-31/elamipretide has an unusually deep human dataset for a peptide, but the results are genuinely mixed. In primary mitochondrial myopathy, the pivotal phase 3 MMPOWER-3 trial (N=218) did NOT meet its co-primary endpoints (6-minute walk distance and a fatigue score). In Barth syndrome, the randomized portion of the TAZPOWER trial also failed its primary endpoints, but a long-term open-label extension reported sustained functional and cardiac improvements, and on the strength of an intermediate strength endpoint the FDA granted accelerated (conditional) approval in September 2025 (brand name Forzinity) for Barth syndrome in patients weighing at least 30 kg. In dry AMD, the phase 2 ReCLAIM-2 trial missed its primary visual and geographic-atrophy endpoints while showing a secondary signal on photoreceptor (ellipsoid zone) preservation. Earlier heart-failure and ischemia work (Bendavia/EMBRACE STEMI era) likewise did not deliver positive pivotal results. Because most primary endpoints were not met and the single approval is accelerated/conditional and disease-specific, the overall human evidence is best described as limited rather than strong, especially for any general wellness, longevity, or energy use, for which there is no approval and no convincing controlled human data.

Animal / lab evidence

Preclinical and in vitro work is extensive and consistently supportive: SS-31 reduces mitochondrial reactive oxygen species, preserves cristae structure and membrane potential, protects against ischemia-reperfusion injury, and improves cardiac and skeletal-muscle mitochondrial function in animal models. These mechanistic and animal findings are the foundation of the cardiolipin-binding model and motivated the human program, but they have translated only partially and inconsistently into clinical benefit.

Key studies

Each summary explains the design, what was found, and what it doesn't prove.

Human RCT2023·218 adults with genetically confirmed primary mitochondrial myopathy, randomized 1:1 to subcutaneous elamipretide 40 mg/day or placebo for 24 weeks
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

In the largest and most rigorous trial of SS-31 for inherited muscle mitochondrial disease, the peptide failed to beat placebo on walking distance or fatigue, which were the main goals. It was safe, but it did not work for the trial population as a whole.

Finding: The pivotal phase 3 trial did NOT meet its co-primary endpoints: there was no significant benefit over placebo on the 6-minute walk test distance or on the total fatigue score. The drug was generally well tolerated, with mostly mild-to-moderate adverse events.
Limitations: Negative pivotal trial for the overall population; benefit, if any, may be confined to specific genetic subgroups identified only in later post hoc analysis; 24-week duration may be short for slowly progressive disease.
Human RCT2024·12 male patients (ages 12-35) with genetically confirmed Barth syndrome; randomized double-blind crossover phase followed by a 168-week open-label extension (10 entered, 8 reached week 168)
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

In this tiny but important Barth syndrome study, SS-31 did not beat placebo in the strictly controlled phase. Over years of open-label use, patients improved on walking and heart measures, but without a comparison group those later gains are harder to trust. This program nonetheless supported the drug's 2025 accelerated approval for Barth syndrome.

Finding: The initial randomized, placebo-controlled phase did NOT meet its primary endpoints (6-minute walk test and fatigue). However, during the long open-label extension, patients showed significant cumulative improvements from extension baseline in the 6-minute walk test and in cardiac and fatigue measures.
Limitations: Very small sample; the positive long-term findings come from an uncontrolled open-label extension (no placebo group), so they cannot rule out practice effects or bias; the controlled portion was negative.
Human RCT2024·Adults with dry age-related macular degeneration and noncentral geographic atrophy; randomized, double-masked, placebo-controlled, daily subcutaneous elamipretide 40 mg for 48 weeks
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation

For dry macular degeneration, SS-31 did not improve vision or slow the main measure of retinal damage compared to placebo. There was a hint it might protect photoreceptor structure, but that is an indirect marker, not proven vision benefit.

Finding: The trial did NOT meet its primary endpoints for visual acuity or geographic atrophy growth. A secondary signal suggested slowing of ellipsoid zone (photoreceptor) degradation, which the sponsor proposed as a future endpoint.
Limitations: Negative for primary endpoints; ellipsoid zone preservation is a surrogate marker whose clinical meaning is not yet established; phase 2 size and 48-week duration limit conclusions about long-term vision benefit.
Human RCT2024·Post hoc subgroup analysis of the MMPOWER-3 randomized trial, grouping participants by genetic subtype (notably mtDNA replisome/maintenance disorders)
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

Researchers reanalyzed the failed mitochondrial myopathy trial and found that one genetic subgroup may have benefited. This is a clue, not proof, and a new dedicated trial was launched to test it properly.

Finding: Although the overall trial was negative, the subgroup with mtDNA replisome (mtDNA maintenance) disorders showed improvement on the 6-minute walk test with elamipretide, motivating a follow-up phase 3 trial (NuPOWER) targeting that genetic subtype.
Limitations: Exploratory, hypothesis-generating post hoc analysis on subgroups of a negative trial; not confirmatory; subgroup sizes are small and results require prospective validation.
Review2025·Narrative review synthesizing preclinical, mechanistic, and clinical literature on elamipretide (SS-31)
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

This review explains why SS-31 was designed and how it targets mitochondria via cardiolipin. It is a useful overview of the science, but it summarizes existing work rather than proving the peptide works in people.

Finding: Summarizes how the tetrapeptide selectively binds cardiolipin in the inner mitochondrial membrane to stabilize cristae, reduce oxidative stress, and enhance ATP production, and reviews its therapeutic potential across mitochondrial-dysfunction diseases.
Limitations: A review, not original controlled data; reflects authors' synthesis and does not by itself establish clinical efficacy; mechanistic promise has not consistently translated into positive pivotal trials.

History

SS-31 originated from the 'Szeto-Schiller' (SS) peptide series developed by Hazel Szeto and Peter Schiller. It was advanced clinically by Stealth BioTherapeutics as MTP-131, studied under the trial name Bendavia in cardiovascular ischemia, and later branded elamipretide across the MMPOWER, TAZPOWER, and ReCLAIM trial programs. After a regulatory path that included a complete response, it received FDA accelerated approval for Barth syndrome (as Forzinity) in September 2025, the first approval of a mitochondria-targeted peptide.

Important:

PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.

Related peptides